Eva Wibbeler
Dr. med.
Eva Wibbeler
  • Fachärztin
  • Fachärztin für Kinder- und Jugendmedizin


Deutsch (Muttersprache)




  • 2022
  • 2021
  • 2020
  • 2018
  • 2012

Visual perception and macular integrity in non-classical CLN2 disease
Atiskova Y, Wildner J, Wibbeler E, Nickel M, Spitzer M, Schwering C, Schulz A, Dulz S
GRAEF ARCH CLIN EXP. 2022;260(11):3693-3700.

Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease)
Dulz S, Schwering C, Wildner J, Spartalis C, Schuettauf F, Bartsch U, Wibbeler E, Nickel M, Spitzer M, Atiskova Y, Schulz A
BRIT J OPHTHALMOL. 2022 [Epub ahead of print].

The Unified Batten Disease Rating Scale (UBDRS): Validation and reliability in an independent CLN3 disease sample
Wibbeler E, Nickel M, Schwering C, Schulz A, Mink J
EUR J PAEDIATR NEURO. 2022;38:62-65.

Investigating health-related quality of life in rare diseases:a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)
Gissen P, Specchio N, Olaye A, Jain M, Butt T, Ghosh W, Ruban-Fell B, Griffiths A, Camp C, Sisic Z, Schwering C, Wibbeler E, Trivisano M, Lee L, Nickel M, Mortensen A, Schulz A
ORPHANET J RARE DIS. 2021;16(1):.

Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients
Schwering C, Kammler G, Wibbeler E, Christner M, Knobloch J, Nickel M, Denecke J, Baehr M, Schulz A
J CHILD NEUROL. 2021;36(8):635-641.

Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease:A Retrospective Case Series
Wibbeler E, Wang R, Reyes E, Specchio N, Gissen P, Guelbert N, Nickel M, Schwering C, Lehwald L, Trivisano M, Lee L, Amato G, Cohen-Pfeffer J, Shediac R, Leal-Pardinas F, Schulz A
J CHILD NEUROL. 2021;36(6):468-474.

An ophthalmic rating scale to assess ocular involvement in juvenile CLN3 disease
Dulz S, Atiskova Y, Wibbeler E, Wildner J, Wagenfeld L, Schwering C, Nickel M, Bartsch U, Spitzer M, Schulz A
AM J OPHTHALMOL. 2020;(220):64-71.

Cardiac pathology in neuronal ceroid lipofuscinoses (NCL): More than a mere co-morbidity
Rietdorf K, Coode E, Schulz A, Wibbeler E, Bootman M, Ostergaard J
BBA-MOL BASIS DIS. 2020;1866(9):.

Study of Intraventricular Cerliponase Alfa for CLN2 Disease
Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, Dyke J, Cahan H, Slasor P, Jacoby D, Kohlschütter A
NEW ENGL J MED. 2018;378(20):1898-1907.

Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: a study of 680 patients
Abicht A, Dusl M, Gallenmüller C, Guergueltcheva V, Schara U, Della Marina A, Wibbeler E, Almaras S, Mihaylova V, von der Hagen M, Huebner A, Chaouch A, Müller J, Lochmüller H
HUM MUTAT. 2012;33(10):1474-84.

Letzte Aktualisierung aus dem FIS: 02.04.2023 - 00:33 Uhr